Abstract: PO0079
Interim Analysis of the COSA Registry: COVID-19 Patients Treated with the Seraph® 100 Microbind® Affinity Filter
Session Information
- COVID-19: Epidemiology, Outcomes, Complications, and Risk Factors
November 04, 2021 | Location: On-Demand, Virtual Only
Abstract Time: 10:00 AM - 12:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Schmidt, Julius, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
- Schmitz, Michael, Stadtisches Klinikum Solingen, Solingen, Nordrhein-Westfalen, Germany
- Kielstein, Jan T., Academic Teaching Hospital Braunschweig, Braunschweig, Germany
Background
The Seraph®100 Microbind Affinity Blood Filter® is a hemofiltration device that is licensed for pathogen reduction in the blood that received an emergency authorization for the treatment of COVID-19 by the FDA. The aim of this registry was to evaluate safety and efficacy of Seraph 100 treatment for COVID-19 patients.
Methods
This is an online registry in which main patient charcteristics, treatment characteristics and outcome parameters of COVID-19 patients, treated with the Seraph100 can be documented without reimbursement.
Results
Seventy-five treatment sessions in 60 patients from 12 hospitals were documented in the registry (Fig 1). Overall mortality was 42.3%. Adverse events of the Seraph® 100 treatment were reported in 8 (10.6 %) of the 75 treatments. Eight (10.6 %) of all the procedures ended prematurely due to circuit failure. Non-survivor had a higher rate of bacterial superinfection, higher level of inflammatory laboratory markers (procalcitonin and ferritin) and higher d-dimer levels(Fig 2). While predicted mortality according to SOFA score in ICU patients was >80 %, the observed mortality was 47.6 %. In non-ICU patients, 4C score predicted a mortality of 31.4-34.9 % while the observed mortality was 22.2 %.
Conclusion
Seraph 100 treatment was well tolerated and circuit failure rate was significantly lower than reported for KRT in COVID-19 patients. Compared to the calculated mortality, the observed mortality in the registry was lower.